Cell Signaling Technology Logo - Extra Large
查看特别推荐 >>
  1. Products /
  2. Primary Antibodies /
  3. TRAIL (C92B9) Rabbit Monoclonal Antibody
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TRAIL (C92B9) Rabbit Monoclonal Antibody #3219

Filter:
  • WB
  • IP
  • IHC
  • IF
  • F

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 28-30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:10 - 1:50
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:800
    Immunofluorescence (Immunocytochemistry) 1:400
    Flow Cytometry (Fixed/Permeabilized) 1:50
    Flow Cytometry (Live) 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #48318.

    Protocol

    Specificity / Sensitivity

    TRAIL (C92B9) Rabbit Monoclonal Antibody detects endogenous levels of total human TRAIL protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys60 of human TRAIL, within the extracellular region of the protein.

    Background

    Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (6,8,10,11) and DcR2 (TRAIL-R4, TRUNDD) (12,13) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (14). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (15,16).
    1. Wiley, S.R. et al. (1995) Immunity 3, 673-82.
    2. Pitti, R.M. et al. (1996) J Biol Chem 271, 12687-90.
    3. Almasan, A. and Ashkenazi, A. Cytokine Growth Factor Rev 14, 337-48.
    4. Pan, G. et al. (1997) Science 276, 111-3.
    5. Walczak, H. et al. (1997) EMBO J 16, 5386-97.
    6. MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
    7. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
    8. Schneider, P. et al. (1997) FEBS Lett 416, 329-34.
    9. Shetty, S. et al. (2002) Apoptosis 7, 413-20.
    10. Sheridan, J.P. et al. (1997) Science 277, 818-21.
    11. Degli-Esposti, M.A. et al. (1997) J Exp Med 186, 1165-70.
    12. Pan, G. et al. (1998) FEBS Lett 424, 41-5.
    13. Marsters, S.A. et al. (1997) Curr Biol 7, 1003-6.
    14. Kelley, S.K. et al. (2001) J Pharmacol Exp Ther 299, 31-8.
    15. Walczak, H. et al. (1999) Nat Med 5, 157-63.
    16. Ashkenazi, A. et al. (1999) J Clin Invest 104, 155-62.

    Alternate Names

    Apo-2 ligand; Apo-2L; APO2L; CD253; chemokine tumor necrosis factor ligand superfamily member 10; Protein TRAIL; TL2; TNF superfamily member 10; TNF-related apoptosis inducing ligand TRAIL; TNF-related apoptosis-inducing ligand; TNF10; TNFSF10; TNLG6A; TRAIL; tumor necrosis factor (ligand) family, member 10; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor apoptosis-inducing ligand splice variant delta; tumor necrosis factor ligand 6A; Tumor necrosis factor ligand superfamily member 10; tumor necrosis factor superfamily member 10

    Database Links

    UniProt ID: P50591


    Entrez-Gene Id: 8743


    限制使用

    除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。

    专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.